Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31751012

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Jan 2
First author
Ramalingam SS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):e15. doi: 10.1016/S1470-2045(19)30778-8.
    note
    Source null
    related pmid
    31787537
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Apr;17(4):202-203. doi: 10.1038/s41571-020-0346-6.
    note
    Source null
    related pmid
    32112056
    relationship
    Comment in
  3. citation
    N Engl J Med. 2020 May 7;382(19):1863. doi: 10.1056/NEJMc2001514.
    note
    Source null
    related pmid
    32374970
    relationship
    Comment in
  4. citation
    N Engl J Med. 2020 May 7;382(19):1863-1864. doi: 10.1056/NEJMc2001514.
    note
    Source null
    related pmid
    32374971
    relationship
    Comment in
  5. citation
    N Engl J Med. 2020 May 7;382(19):1864. doi: 10.1056/NEJMc2001514.
    note
    Source null
    related pmid
    32374972
    relationship
    Comment in

Authors and identifiers

  1. name
    Ramalingam SS
    type
    Author
  2. name
    Vansteenkiste J
    type
    Author
  3. name
    Planchard D
    type
    Author
  4. name
    Cho BC
    type
    Author
  5. name
    Gray JE
    type
    Author
  6. name
    Ohe Y
    type
    Author
  7. name
    Zhou C
    type
    Author
  8. name
    Reungwetwattana T
    type
    Author
  9. name
    Cheng Y
    type
    Author
  10. name
    Chewaskulyong B
    type
    Author
  11. name
    Shah R
    type
    Author
  12. name
    Cobo M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ramalingam SS
    type
    Author
  2. name
    Vansteenkiste J
    type
    Author
  3. name
    Planchard D
    type
    Author
  4. name
    Cho BC
    type
    Author
  5. name
    Gray JE
    type
    Author
  6. name
    Ohe Y
    type
    Author
  7. name
    Zhou C
    type
    Author
  8. name
    Reungwetwattana T
    type
    Author
  9. name
    Cheng Y
    type
    Author
  10. name
    Chewaskulyong B
    type
    Author
  11. name
    Shah R
    type
    Author
  12. name
    Cobo M
    type
    Author
bibliography ids
  1. nci-bib-a9eb47662c9a593155c68919
book metadata
content sha256
6f7a3cde28ca7dfba8c01b55b4d01eb33c27f6f1ae1eeb60a7e074cf814249a6
document type
citation
dois
  1. 10.1056/NEJMoa1913662
electronic publication date
display
2019 Nov 21
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31751012
immutable id
pubmed:31751012@6f7a3cde28ca7dfba8c01b55b4d01eb33c27f6f1ae1eeb60a7e074cf814249a6
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
1
name
The New England journal of medicine
nlm unique id
0255562
pages
41-50
volume
382
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jan;21(1):e15. doi: 10.1016/S1470-2045(19)30778-8.
    note
    Source null
    related pmid
    31787537
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Apr;17(4):202-203. doi: 10.1038/s41571-020-0346-6.
    note
    Source null
    related pmid
    32112056
    relationship
    Comment in
  3. citation
    N Engl J Med. 2020 May 7;382(19):1863. doi: 10.1056/NEJMc2001514.
    note
    Source null
    related pmid
    32374970
    relationship
    Comment in
  4. citation
    N Engl J Med. 2020 May 7;382(19):1863-1864. doi: 10.1056/NEJMc2001514.
    note
    Source null
    related pmid
    32374971
    relationship
    Comment in
  5. citation
    N Engl J Med. 2020 May 7;382(19):1864. doi: 10.1056/NEJMc2001514.
    note
    Source null
    related pmid
    32374972
    relationship
    Comment in
outcomes validated
false
pmid
31751012
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
a7b1c8551c1a48c81e978e4846768593912ab64f31b217921950463dabf16903
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2020 Jan 2
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31751012/
title
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Preserved source evidence · Not medical advice